Abiopharma

🔍 Zbanek Cathy W (Executive)

Company: TFS Financial CORP (TFSL)

Report Date: 2026-06-09

Detailed Transactions and Holdings:

• Acquired 60,000 shares of Common Stock at $14.74 per share (Direct)
  Date: 2026-06-09 | Code: M | equity_swap_involved: 0 | shares_owned_after: 124,352.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 55,533 shares of Common Stock at $16.49 per share (Direct)
  Date: 2026-06-09 | Code: F | equity_swap_involved: 0 | shares_owned_after: 68,819.00 | transaction_form_type: 4 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-09 | Code: H | nature_of_ownership: By ESOP | shares_owned_after: 14,234.00 | Footnotes: F3
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-06-09 | Code: H | nature_of_ownership: By 401(k) | shares_owned_after: 5,323.00 | Footnotes: F3
• Sold 60,000 shares of Employee Stock Option (right to buy) at $14.74 per share (Derivative)
  Date: 2026-06-09 | Code: M | Expires: 2028-01-05 | equity_swap_involved: 0 | shares_owned_after: 67,500.00 | transaction_form_type: 4 | Footnotes: F4
• Holds 15,800 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-09 | Code: H | shares_owned_after: 15,800.00 | Footnotes: F5, F6, F6
• Holds 4,734 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-09 | Code: H | shares_owned_after: 4,734.00 | Footnotes: F5, F7, F7
• Holds 10,600 shares of Restricted Stock Units (Derivative)
  Date: 2026-06-09 | Code: H | shares_owned_after: 10,600.00 | Footnotes: F5, F8, F8
• Holds 12,400 shares of Performance Restricted Share Units (Derivative)
  Date: 2026-06-09 | Code: H | shares_owned_after: 12,400.00 | Footnotes: F5, F9, F9
• Holds 79,400 shares of Employee Stock Option (right to buy) at $19.31 per share (Derivative)
  Date: 2026-06-09 | Code: H | Expires: 2026-12-15 | shares_owned_after: 79,400.00 | Footnotes: F10

Footnotes:

• F1: These common shares were acquired upon the exercise and settlement of certain stock options.
• F2: These common shares were delivered to the issuer to pay for the options exercise price and applicable withholding tax due upon the exercise of certain stock options.
• F3: Reflects transactions not required to be reported under Section 16 of the Securities Exchange Act, as amended.
• F4: As reported on a Form 4 dated January 8, 2018, the reporting person received a grant of 187,500 stock options. These stock options vest in three equal annual installments beginning December 10, 2018.
• F5: Each restricted and performance stock unit represents a contingent right to receive one share of TFS Financial Corporation common stock. Restricted and performance stock units are entitled to dividend equivalent rights in the form of a cash payment in the amount of any cash dividend paid per share of common stock.
• F6: On December 18, 2025, the reporting person received a grant of 15,800 Restricted Stock Units (RSUs). These RSUs vest in three equal annual installments beginning December 10, 2026.
• F7: On March 4, 2024, the reporting person received a grant of 14,200 Restricted Stock Units (RSUs). These RSUs vest in three equal annual installments beginning December 10, 2024.
• F8: On December 19, 2024, the reporting person received a grant of 15,900 Restricted Stock Units (RSUs). These RSUs vest in three equal annual installments beginning December 10, 2025.
• F9: On November 25, 2025, the reporting person achieved performance level of 100% on a target award of 12,400 Performance Share Units ("PSUs"), resulting in a total earned award of 12,400 shares. This represents the final determination a March 4, 2024 award that was dependent on certain performance results during the two fiscal year period ended September 30, 2025. Each PSU represents a contingent right to receive one share of TFS Financial Corporation common stock and are entitled to dividend equivalent rights in the form of a cash payment in the amount of any cash dividend paid per share of common stock during the period the award was outstanding. The shares and dividend equivalent payment will vest and distribute to the reporting person on December 10, 2026.
• F10: As reported on a Form 4 dated December 15, 2016, the reporting person received a grant of 79,400 stock options. These stock options vest in three equal annual installments beginning December 10, 2017.